Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination vaccine containing **inactivated, split virion influenza A (H1N1) 2009** virus antigen and the **MF59 adjuvant**. The vaccine is formulated to confer immunity against the A/California/7/2009 (H1N1)v-like strain. MF59 is an oil-in-water emulsion adjuvant made primarily of squalene oil, which enhances immune response by promoting the recruitment of innate immune cells, facilitating antigen uptake and presentation, and inducing both humoral and cellular immunity. The combined effect results in higher and broader antibody titers, increased CD4+ T-cell priming, and more effective vaccination, especially in populations such as children and the elderly[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza A (H1N1) 2009 vaccine + MF59.